• Le 04 October 2022
    Amphi Ricordeau
    false false
  • Titre : “Therapeutic applications of extracellular vesicles : from bioproduction to biotherapies”.
    Mardi 4 octobre 2022 à 11H,

Dr Amanda SILVA BRUN – Dr Florence GAZEAU Laboratoire Matière et Systèmes Complexes (UMR 7057), Paris Titre : “Therapeutic applications of extracellular vesicles : from bioproduction to biotherapies”. Invitées par le Dr Sophie Brouard

Amanda Silva Brun obtained a Pharmacy degree in 2005, a PhD on Pharmaceutical Technology in 2008 and a second PhD in Cellular and Molecular Biology in 2010. Amanda obtained a tenured CNRS researcher position in France in 2013 and a senior CNRS researcher position in 2022. She works at Laboratoire Matière et Systèmes Complexes (MSC, UMR 7057) at the team MSC-MED and IVETh integrateur leaded by Florence Gazeau at Université Paris Cité, mainly focusing on high-performance approaches for (i) extracellular vesicle (EV) production based on a turbulent flow stimulation directly in bioreactors; (ii) EV loading for anti-tumor therapy as well as (iii) EV administration in a hydrogel for regenerative medicine (fistula therapy and esophageal stricture prevention). This research set the basis and the patent portfolio (4 licensed patent applications) for founding 2 spin-offs: EverZom (a bio-production start-up – 16 employees) and Evora Bioscience (a biotherapy start-up – 6 employees). Amanda contributes to them as chief scientific officer (CSO). Amanda was awarded the CNRS Innovation Medal in 2021 and “Prix des innovateurs en santé” from Région Île-de-France in 2020.  Amanda is the Vice-President of the French Society for Nanomedicine (SFNano). Amanda has recently launched and co-coordinated the group “Extracellular Vesicle translatiOn to clinicaL perspectiVEs – EVOLVE France” together with a clinician colleague to address regulatory issues on EV-based biotherapies. Amanda co-coordinates the associative project DIM Bioconvergence pour la Santé (12.5 M€) structuring and accelerating innovation on bioproduction, biotherapies and synthetic biology at Region Ile de France.  Amanda published 70 papers. Her current research project on EV bioengineering is funded by an ERC grant.

Florence Gazeau, PhD in solid state physics (Université Paris Diderot, 1997) is senior scientist at CNRS. She is deputy director of the lab Matière et Systèmes Complexes (MSC) UMR7057 CNRS / Université Paris Cité.  She has created the antenna MSC Med (https://msc-med.u-paris.fr/) on the Campus Saint Germain (45 rue des Saints Pères) in order to promote translational research and innovation in nanomedicine and subcellular biotherapies. Amanda Silva Brun and Florence Gazeau launched in   2020 the first expertise platform (https://iveth.u-paris.fr) dedicated to the bioproduction, characterization and engineering of extracellular vesicles and nanovectors for the diagnostic et personalized therapies. The IVETh platform has been labeled as national industrial integrator for bioproduction and biotherapies en 2022. F. Gazeau participated to the creation of two spin-off : EVerzom for the industrial bioproduction of extracellular vesicles with the technology of turbulence and Evora Bioscience for the development of EV-based biotherapies. Florence Gazeau is recognized for her pioneering works in nanomagnetism and nanotechnology applied to medecine (magnetic labelling of cells, MRI tracking of cell migration in vivo,  magnetic cell manipulation for tissue engineering, photo-induced or magnetic hyperthermia to modulate the tumor microenvironment in cancer treatment).She initiated the first multiscale follow-up of the fate and life cycle (degradation, recycling, rebiomineralization) of metallic nanoparticles in the organism. The group exploits a biomimetic strategy with biogenic EVs from immune or stem cells for targeted and optimized drug or protein delivery. Florence Gazeau is author of more than 180 international publications with more than 15000 citations and 8 patents among which 4 have been licensed.